MetaShape Pharma is a Swiss company developing first-in-class NAD+ restoration therapies for aging disorders to power lifelong health. The company's technology holds great promise for patients suffering from or at risk of cardiovascular, metabolic and neurodegenerative conditions.

The company's lead compound, MS 001, is a potent and selective inhibitor of purine nucleoside phosphorylase (PNP) and is the first disease-targeting therapy that reliably restores cellular availability of NAD+.